Summary

Persistence Market Research has recently released a comprehensive report on the worldwide market for swine autogenous vaccines. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global swine autogenous vaccines market from 2025 to 2032.

Key Insights:

• Swine Autogenous Vaccines Market Size (2025E): USD 48.7 Million
• Projected Market Value (2032F): USD 70.0 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 5.3%

Swine Autogenous Vaccines Market – Report Scope:

Swine autogenous vaccines are custom-made vaccines developed using pathogens isolated from a specific herd. These vaccines provide targeted immunity against local disease strains that may not be addressed by commercial vaccines. They are commonly used in swine herds to combat bacterial and viral infections such as swine dysentery, Mycoplasma hyopneumoniae, Streptococcus suis, and porcine reproductive and respiratory syndrome (PRRS). The market caters to commercial swine producers, veterinary clinics, and animal health companies, with growth driven by increasing disease incidence, rising demand for herd-specific solutions, and a greater focus on biosecurity and animal health management.

Market Growth Drivers:

The global swine autogenous vaccines market is propelled by the rising prevalence of infectious diseases in swine populations, often exacerbated by high-density farming practices and antibiotic resistance. These vaccines offer swine producers a strategic tool to address region-specific pathogens and reduce antibiotic use, aligning with global efforts to combat antimicrobial resistance (AMR). Additionally, growing awareness of preventive veterinary care, increasing swine production for meat consumption, and the inadequacy of one-size-fits-all commercial vaccines are prompting livestock farmers to adopt personalized vaccination strategies. Regulatory support for autogenous vaccine manufacturing and use is further facilitating market growth.

Market Restraints:

Despite favorable market conditions, the swine autogenous vaccines market faces several challenges. Regulatory barriers and complex approval processes for autogenous vaccine production vary significantly by country, potentially limiting cross-border applications. The production of autogenous vaccines is time-intensive and demands advanced biosafety and diagnostic capabilities, which can be cost-prohibitive for small farms. Moreover, limited shelf life and lack of standardized protocols for production, storage, and distribution can restrict vaccine effectiveness and scalability. These issues necessitate improvements in infrastructure, diagnostic speed, and regulatory harmonization to sustain market momentum.

Market Opportunities:

The market presents substantial growth opportunities through the integration of molecular diagnostics and next-generation sequencing (NGS) technologies, which enable faster identification of herd-specific pathogens. The adoption of precision livestock farming and herd health monitoring systems supports the tailored application of autogenous vaccines, enhancing animal health outcomes and operational efficiency. Emerging markets, particularly in Asia-Pacific and Latin America, offer untapped potential due to increasing pork consumption and expanding commercial swine production. Strategic partnerships between veterinary service providers, research institutions, and biotechnology firms can accelerate innovation, streamline vaccine development, and enhance market access.

Key Questions Answered in the Report:

• What are the major factors driving the global swine autogenous vaccines market?
• Which diseases are most commonly targeted using autogenous vaccines in swine?
• How are advancements in diagnostics and biotechnology influencing vaccine development?
• Who are the key players in the swine autogenous vaccines market, and what strategies are they employing for growth?
• What are the regional trends and future opportunities shaping this market?

Competitive Intelligence and Business Strategy:

Leading players in the global swine autogenous vaccines market, including Newport Laboratories (Boehringer Ingelheim), Cambridge Technologies, Elanco Animal Health, and Huvepharma, focus on expanding their custom vaccine development capabilities and enhancing diagnostic support services. These companies are investing in research and development to create faster, safer, and more effective vaccine solutions tailored to farm-level disease profiles. Collaboration with veterinarians and animal health organizations ensures a continuous supply of herd-specific vaccines. Furthermore, companies are exploring digital platforms for vaccination records, herd management, and diagnostics integration to strengthen client engagement and treatment efficacy.

Key Companies Profiled:

• Ceva
• Phibro Animal Health Corporation
• SAN Group Biotech Germany GmbH
• Exopol
• Vaxxinova
• ?American Animal Health, Inc.
• BIMEDA® BIOLOGICALS
• Dopharma
• Elanco
• Tréidlia Biovet
• Cambridge Technologies
• Addison Biological Laboratory
• VST Labs
• INVAC Deutschland GmbH
• Merck & Co., Inc.
• Wixbio
• Boehringer Ingelheim Animal Health USA Inc.
• Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH
• Dyntec
• Aptimmune

Market Segmentation

By Strain Type

• Bacterial Strain
• Viral Strain

By Application

• Respiratory Diseases
• Gastrointestinal Diseases
• Reproductive Diseases
• Systemic Infections
• Others

By End-user

• Veterinary Clinics and Hospitals
• Livestock Farming Companies
• Research and Academic Institutes

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Swine Autogenous Vaccines Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Product Adoption Analysis
3.2. Disease Epidemiology
3.3. Technological Advancement
3.4. Regulatory Landscape
3.5. Value Chain Analysis
3.6. Key Deals and Mergers
3.7. PESTLE Analysis
3.8. Porter’s Five Force Analysis
4. Global Swine Autogenous Vaccines Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global Swine Autogenous Vaccines Market Outlook: Strain Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, by Strain Type, 2019-2024
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
4.3.3.1. Bacterial Strain
4.3.3.2. Viral Strain
4.3.4. Market Attractiveness Analysis: Strain Type
4.4. Global Swine Autogenous Vaccines Market Outlook: Application
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Mn) Analysis, by Application, 2019-2024
4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
4.4.3.1. Respiratory Diseases
4.4.3.2. Gastrointestinal Diseases
4.4.3.3. Reproductive Diseases
4.4.3.4. Systemic Infections
4.4.3.5. Others
4.4.4. Market Attractiveness Analysis: Application
4.5. Global Swine Autogenous Vaccines Market Outlook: End User
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, by End User, 2019-2024
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
4.5.3.1. Veterinary Clinics and Hospitals
4.5.3.2. Livestock Farming Companies
4.5.3.3. Research and Academic Institutes
4.5.4. Market Attractiveness Analysis: End User
5. Global Swine Autogenous Vaccines Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, by Region, 2019-2024
5.3. Current Market Size (US$ Mn) Analysis and Forecast by Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Swine Autogenous Vaccines Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
6.2.1. by Country
6.2.2. by Strain Type
6.2.3. by Application
6.2.4. by End User
6.3. Current Market Size (US$ Mn) Analysis and Forecast by Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast by Strain Type, 2025-2032
6.4.1. Bacterial Strain
6.4.2. Viral Strain
6.5. Current Market Size (US$ Mn) Analysis and Forecast by Application, 2025-2032
6.5.1. Respiratory Diseases
6.5.2. Gastrointestinal Diseases
6.5.3. Reproductive Diseases
6.5.4. Systemic Infections
6.5.5. Others
6.6. Current Market Size (US$ Mn) Analysis and Forecast by End User, 2025-2032
6.6.1. Veterinary Clinics and Hospitals
6.6.2. Livestock Farming Companies
6.6.3. Research and Academic Institutes
6.7. Market Attractiveness Analysis
7. Europe Swine Autogenous Vaccines Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
7.2.1. by Country
7.2.2. by Strain Type
7.2.3. by Application
7.2.4. by End User
7.3. Current Market Size (US$ Mn) Analysis and Forecast, by Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
7.4.1. Bacterial Strain
7.4.2. Viral Strain
7.5. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
7.5.1. Respiratory Diseases
7.5.2. Gastrointestinal Diseases
7.5.3. Reproductive Diseases
7.5.4. Systemic Infections
7.5.5. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
7.6.1. Veterinary Clinics and Hospitals
7.6.2. Livestock Farming Companies
7.6.3. Research and Academic Institutes
7.7. Market Attractiveness Analysis
8. East Asia Swine Autogenous Vaccines Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
8.2.1. by Country
8.2.2. by Strain Type
8.2.3. by Application
8.2.4. by End User
8.3. Current Market Size (US$ Mn) Analysis and Forecast, by Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
8.4.1. Bacterial Strain
8.4.2. Viral Strain
8.5. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
8.5.1. Respiratory Diseases
8.5.2. Gastrointestinal Diseases
8.5.3. Reproductive Diseases
8.5.4. Systemic Infections
8.5.5. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
8.6.1. Veterinary Clinics and Hospitals
8.6.2. Livestock Farming Companies
8.6.3. Research and Academic Institutes
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Swine Autogenous Vaccines Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
9.2.1. by Country
9.2.2. by Strain Type
9.2.3. by Application
9.2.4. by End User
9.3. Current Market Size (US$ Mn) Analysis and Forecast, by Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
9.4.1. Bacterial Strain
9.4.2. Viral Strain
9.5. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
9.5.1. Respiratory Diseases
9.5.2. Gastrointestinal Diseases
9.5.3. Reproductive Diseases
9.5.4. Systemic Infections
9.5.5. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
9.6.1. Veterinary Clinics and Hospitals
9.6.2. Livestock Farming Companies
9.6.3. Research and Academic Institutes
9.7. Market Attractiveness Analysis
10. Latin America Swine Autogenous Vaccines Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
10.2.1. by Country
10.2.2. by Strain Type
10.2.3. by Application
10.2.4. by End User
10.3. Current Market Size (US$ Mn) Analysis and Forecast, by Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
10.4.1. Bacterial Strain
10.4.2. Viral Strain
10.5. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
10.5.1. Respiratory Diseases
10.5.2. Gastrointestinal Diseases
10.5.3. Reproductive Diseases
10.5.4. Systemic Infections
10.5.5. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
10.6.1. Veterinary Clinics and Hospitals
10.6.2. Livestock Farming Companies
10.6.3. Research and Academic Institutes
10.7. Market Attractiveness Analysis
11. Middle East & Africa Swine Autogenous Vaccines Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, by Market, 2019-2024
11.2.1. by Country
11.2.2. by Strain Type
11.2.3. by Application
11.2.4. by End User
11.3. Current Market Size (US$ Mn) Analysis and Forecast, by Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, by Strain Type, 2025-2032
11.4.1. Bacterial Strain
11.4.2. Viral Strain
11.5. Current Market Size (US$ Mn) Analysis and Forecast, by Application, 2025-2032
11.5.1. Respiratory Diseases
11.5.2. Gastrointestinal Diseases
11.5.3. Reproductive Diseases
11.5.4. Systemic Infections
11.5.5. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, by End User, 2025-2032
11.6.1. Veterinary Clinics and Hospitals
11.6.2. Livestock Farming Companies
11.6.3. Research and Academic Institutes
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping by Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Ceva
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Phibro Animal Health Corporation
12.3.3. SAN Group Biotech Germany GmbH
12.3.4. Exopol
12.3.5. Vaxxinova
12.3.6. ?American Animal Health, Inc.
12.3.7. BIMEDA® BIOLOGICALS
12.3.8. Dopharma
12.3.9. Elanco
12.3.10. Tréidlia Biovet
12.3.11. Cambridge Technologies
12.3.12. Addison Biological Laboratory
12.3.13. VST Labs
12.3.14. INVAC Deutschland GmbH
12.3.15. Merck & Co., Inc.
12.3.16. Wixbio
12.3.17. Boehringer Ingelheim Animal Health USA Inc.
12.3.18. Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH
12.3.19. Dyntec
12.3.20. Aptimmune
12.3.21. Others
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations